Hospitals call Boehringer Ingelheim’s contract pharmacy plans “appalling” while company calls for “substantial reform” of the 340B program.

Breaking News

Boehringer Ingelheim Will Stop Shipping 340B Drugs to Hospitals’ Contract Pharmacies on Aug. 1

Drug manufacturer Boehringer Ingelheim (BI) announced yesterday that it will stop shipping 340B-purchased drugs to hospitals’ contract pharmacies, effective Aug. 1.

Community health centers, HIV/AIDS clinics, and other federal grantee covered entities are exempt from BI’s new policy. It applies to all BI products except the company’s specialty drugs OFEV, Gilotrif, and Praxbind. BI will let hospitals without an in-house pharmacy designate a single contract pharmacy location to receive and dispense BI products. Hospitals will have to register with drug manufacturer vendor 340B ESP to make their contract pharmacy designation.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

*Sign up for news summaries and alerts from 340B Report